Memantine Aurobindo

Memantine hydrochloride, the active ingredient in Memantine Aurobindo, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults. The medication works by modulating glutamatergic activity in the brain and is typically administered once daily as part of standard therapeutic regimens for cognitive decline associated with Alzheimer’s disease.\n\nGNH India supplies Memantine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Memantine, an NMDA receptor antagonist, is used in the management of Alzheimer’s disease, the most common cause of dementia.\nAlzheimer’s disease (moderate to severe): provides symptomatic improvement in cognition, memory, language, and the ability to perform daily activities, helping to maintain functional independence and may delay progression of functional decline for as long as possible.\nAlzheimer’s disease with behavioral disturbances: may reduce agitation, aggression, and psychotic symptoms, and may improve sleep quality, contributing to overall patient and caregiver management.

Memantine may be associated with several adverse reactions, most of which are mild, reversible, and dose‑dependent in many patients.\n\nCommon Side Effects:\n- Dizziness: a transient sensation of light‑headedness that usually resolves without intervention.\n- Headache: mild to moderate pain often alleviated by simple analgesics.\n- Constipation: reduced bowel movements that can be managed with dietary fiber or laxatives.\n\nSerious or Rare Side Effects:\n- Severe skin reactions (e.g., Stevens‑Johnson syndrome or toxic epidermal necrolysis): require immediate medical attention and discontinuation of therapy.\n- Seizures: new‑onset convulsions that may necessitate neurologic evaluation and possible cessation of the drug.\n- Hepatic dysfunction: elevated liver enzymes or hepatitis, monitored through laboratory testing and may need drug withdrawal.

When prescribing Memantine, clinicians should consider several precautionary measures to ensure patient safety.\nRenal impairment: adjust dose or monitor renal function in patients with reduced clearance.\nConcomitant CNS disorders: use caution in patients with a history of seizures or psychosis.\nCardiovascular disease: monitor blood pressure and heart rate as dizziness may affect hemodynamics.\nPregnancy and lactation: safety has not been established; avoid use unless potential benefit justifies potential risk.\nStore at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medicines, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Amantadine: concurrent use may lead to additive NMDA antagonism and increase risk of dizziness, confusion, or other CNS adverse effects.\n- Ketamine: combined NMDA blockade can result in severe neuropsychiatric reactions and should be avoided.\n\nModerate Interactions (Monitor Closely):\n- Anticholinesterase inhibitors (e.g., donepezil, rivastigmine): may require dose adjustment as combined therapy can affect cognitive outcomes.\n- Loop diuretics (e.g., furosemide): reduced renal clearance may raise memantine plasma levels, necessitating monitoring.\n- Central nervous system depressants (e.g., benzodiazepines): may enhance sedation and dizziness, warranting careful observation.